Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund. The gift was authorized on June 16, 2026, and transferred on June 22, 2026, at a reported price of $0.00 per share. Following this charitable transfer, Inrig directly holds 112,770 shares of Travere Therapeutics common stock, indicating this was a relatively small, non-market transaction within her overall position.
Travere Therapeutics director Timothy Coughlin reported an option exercise combined with a share sale. He exercised stock options for 10,000 shares of common stock at an exercise price of $26.52 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $50.0747 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance. Following these transactions, Coughlin directly holds 56,250 shares of Travere Therapeutics common stock.
Travere Therapeutics director Roy D. Baynes reported an options exercise and share sale. On the same date, he exercised stock options to acquire 4,500 shares of common stock at $21.38 per share and sold 4,500 shares in an open-market transaction at $50.00 per share.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, Baynes directly holds 41,500 shares of Travere Therapeutics common stock.
Travere Therapeutics announced that Chief Research Officer William Rote, Ph.D. plans to retire from the company effective February 17, 2027, which marks the 10-year anniversary of his employment. He is expected to remain in his current role until that date and support a smooth transition.
The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the company’s Chief Medical Officer. Effective July 1, 2026, Dr. Inrig will be named Executive Vice President, Head of Research & Development and Chief Medical Officer. Travere also expects to enter into a consulting arrangement with Dr. Rote following his retirement to maintain access to his expertise.
Roy Baynes filed a Form 144 notice to sell 4,500 shares of Common Stock via a stock option exercise scheduled for 06/12/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned method of payment is cash.
Recent sales by the same holder include 4,500, 9,750, 32,750, and 10,000 shares on dates in 04/06/2026–05/05/2026, with reported proceeds shown in dollars.
TVTX submitted a Form 144 notice reporting an intended sale of up to 10,000 shares and disclosing a sale of 3,250 common shares on 05/15/2026 for $141,182.59. The filing names Wells Fargo Clearing Services as the broker and lists the securities as stock options dated 05/09/2018.
Travere Therapeutics entered a major license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), a covalent reversible Bruton’s tyrosine kinase inhibitor. Travere receives exclusive rights to develop and commercialize the drug for prophylactic, diagnostic and therapeutic uses in a broad field across territories outside China and certain East and Southeast Asian countries.
Travere will pay Everest an upfront $112.5 million, with Everest eligible for up to approximately $1.03 billion in additional clinical, regulatory and commercial milestone payments across up to five indications, plus tiered royalties from high single-digit to double-digit percentages on net sales. Travere leads development and commercialization in its territory, shares costs for global trials, and both parties agree to a 10‑year non-compete on competing BTK products. The agreement becomes effective after customary conditions, including expiration or termination of the Hart‑Scott‑Rodino waiting period.
Travere Therapeutics, Inc. director Ruth Williams Brinkley received an automatic equity grant under the company’s 2018 Equity Incentive Plan pursuant to its non-employee director compensation program. The award includes 4,000 shares of common stock and stock options for 12,000 shares at an exercise price of $42.26 per share.
The equity award vests over a one-year period. The stock options become exercisable beginning on May 19, 2027 and expire on May 19, 2036. Following the stock grant, Brinkley directly holds 29,750 shares of Travere Therapeutics common stock.
Travere Therapeutics director Ron Squarer received new equity compensation. He was granted 4,000 shares of common stock as an automatic equity grant under the company’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.
Squarer was also granted stock options covering 12,000 shares of common stock with a conversion price of $42.26 per share. The equity award vests over a one-year period, and the options are exercisable from May 2027 and expire in May 2036, reflecting routine board-level compensation rather than open-market trading.
Travere Therapeutics director Sandra Poole received equity compensation in the form of shares and options. On May 19, 2026, she was granted 4,000 shares of common stock at no cost under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program. Following this grant, she directly holds 34,000 common shares. On the same date, she also received a stock option for 12,000 shares of common stock with an exercise price of $42.26 per share, expiring in 2036. The award vests over one year, indicating a time-based service requirement rather than an open-market purchase.